JAMA Netw Open
Do dapagliflozin and empagliflozin differ in heart failure outcomes?
In a propensity score–matched cohort study of 4,930 patients with heart failure (HF) across eight Korean medical centers, dapagliflozin and empagliflozin showed no significant difference in the composite outcome of cardiovascular death or HF hospitalization (9.8% vs. 9.3%; adjusted hazard ratio, 0.99; 95% confidence interval, 0.83-1.19; P=.95). Median follow-up was 16 months. Results were consistent across left ventricular ejection fraction (LVEF) subgroups and secondary outcomes, with similar safety profiles.
Clinical takeaway: Dapagliflozin and empagliflozin offer comparable effectiveness in the management of HF in routine clinical practice; however, further research and clinical trials are necessary to validate the findings and inform clinical decision-making.
Source:
Bu S, et al. (2025, December 1). JAMA Netw Open. Empagliflozin and Dapagliflozin Outcomes in Heart Failure. https://pubmed.ncbi.nlm.nih.gov/41343213/